To add more, A current ongoing clinical trial in a phase 2 phase is investigating the role of FGF19 analogue as a reversal drug in MASH and liver fibrosis; further trials are currently underway [288]. The gene discussed is FGF19; the disease is metabolic dysfunction-associated steatohepatitis.